St. Jude Care & Treatment

Menu

Close

Recruiting

SENSURV: Improving Frailty in Childhood Cancer Survivors

About this study

This study is being done to help childhood cancer survivors with frailty. Frailty means a person has weaker muscles, slower walking speed, and reduced physical function. While everyone gets frail as they age, research shows that childhood cancer survivors may become frail earlier than usual. Right now, there is no standard way to treat this problem. So, scientists are looking for new ways to help survivors stay stronger and healthier longer.

In this clinical trial, we will test 2 treatments to see if they can help improve frailty:

  • One group of participants will take 2 drugs called dasatinib and quercetin. 
  • Another group will take 1 drug called fisetin. 

Scientists will measure whether these drugs help people walk faster and if they reduce a specific blood protein called p16. High levels of p16 are linked to aging and frailty. If the drugs lower this protein, they might help survivors stay stronger.

People in the study will complete physical, neurological, and medical tests. They will also take the study drugs on 6 different days and have blood drawn. 

This study may help doctors learn more about new ways to improve health in childhood cancer survivors. It could lead to treatments that help others in the future. 

Eligibility overview

  • 18 years and older
  • SJLIFE study participant
  • Considered frail based on certain physical tests
  • Immune cells contain a certain level of a protein called p16INK4A  

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

SEN-SURVIVORS: An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer

Study goal:

To study whether a combination of dasatinib and quercetin or fisetin alone can reduce signs of frailty in childhood cancer survivors. 

Diagnosis:

Childhood cancer

Age:

18 years and older

Clinical trials categories:

Childhood Cancer

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more